Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Nussenzweig: Discovery & Characterization of bNAbs |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | In Progress |
| Study Start Date: | 2015-09-09 |
| Study Made Public: | 2019-04-16 |
Title
A phase 1, open label, dose-escalation study of the safety, pharmacokinetics and antiretroviral activity of 10-1074 monoclonal antibody in HIV-infected and HIV-uninfected individuals
Description
CAVD 514 (Protocol MCA-0885) is a Phase 1 open-label, dose escalation clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the highly neutralizing anti-HIV-1 monoclonal antibody 10-1074 in HIV-infected and HIV-uninfected individuals..
Sign in to see full information about this study and to download study data.
Products
10-1074Integrated data
PK MAb, NAb MAb
Non-integrated data
Viral load, Demographics (Supplemental)